NGL Fine-Chem Limited has reported its audited financial results for the quarter and year ended March 31, 2026. The company's consolidated net profit for the year surged to ₹4,812.67 lakh, a significant increase of 128% from ₹2,112.43 lakh in the previous year. Revenue from operations for the year stood at ₹51,568.29 lakh compared to ₹37,688.70 lakh in FY25. The board has recommended a final dividend of ₹1.75 per share.

Financial Performance

For the quarter ended March 31, 2026, NGL Fine-Chem delivered a strong operational performance, with Q4 revenue rising 61.4% year-on-year to ₹15,169.20 lakh. This growth was driven entirely by volume expansion, marking the third consecutive quarter of robust volume growth. Q4 EBITDA increased to ₹214.10 lakh from ₹63.20 lakh in the same period last year. The EBITDA margin expanded to 14.1% from 6.7% year-on-year. Consolidated net profit for the quarter came in at ₹1,348.56 lakh, compared to ₹54.36 lakh in the corresponding quarter of the previous year.

The following table summarises the key consolidated financial metrics for the full year and the quarter:

Operational Highlights

The company reported that Animal API segment revenue constituted 95% of the total mix in Q4FY26. Geographically, Asia accounted for 43% of the revenue, followed by India at 23% and Rest of the World at 26%. Management noted that while geopolitical volatility increased freight and raw material costs, partial price pass-through was achieved in the first quarter. Phase I of the capex programme is contributing to operations, while Phase II commissioning is now scheduled for early Q2FY27.

Key Meeting Decisions

The board has scheduled the 45th Annual General Meeting (AGM) for Tuesday, August 25, 2026, via Video Conferencing. The record date for determining eligibility for the AGM and dividend payment is Tuesday, August 18, 2026. The register of members and share transfer books will remain closed from Wednesday, August 19, 2026, to Tuesday, August 25, 2026. Additionally, the board approved the reappointment of Mr. Rajesh Lawande as Whole-Time Director and Mrs. Sarala Menon as Independent Director, subject to shareholder approval.

NGL Fine-Chem Limited has submitted its mandatory compliance certificate to stock exchanges for the quarter ended March 31, 2026. The pharmaceutical company filed the certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 on April 6, 2026.

Regulatory Filing Details

The compliance certificate was submitted to both major Indian stock exchanges where the company's shares are listed. Company Secretary Shivam Gharat signed the submission letter on behalf of NGL Fine-Chem Limited.

Certificate Confirmation

Purva Sharegistry (India) Pvt. Ltd., serving as the company's Registrar and Share Transfer Agent, issued the compliance certificate on April 1, 2026. The certificate confirms adherence to SEBI regulations regarding dematerialisation processes during the quarter.

Regulatory Compliance Framework

The certificate validates that securities received from depository participants for dematerialisation were properly processed during the quarter ended March 31, 2026. Purva Sharegistry confirmed that all security certificates were appropriately mutilated and cancelled after verification by depository participants.

Ms. Deepali Gaonkar, Compliance Officer at Purva Sharegistry, signed the confirmation certificate, ensuring that the company's register of members was updated with depositories' names as registered owners within prescribed timelines. This regulatory filing demonstrates NGL Fine-Chem Limited's continued compliance with SEBI's depositories and participants regulations.